or national centers, or would otherwise benefit from strategic coordination and planning. The bill would authorize $12.6 million out of the 10-Year Pediatric Research Initiative Fund for each of FY2014-FY2023 for pediatric research through the Common Fund. Requires such funds to supplement, not supplant, funds otherwise allocated by NIH for pediatric research. Prohibits the use of such amounts for any purpose other than allocating funds for making grants for pediatric research described in this Act. Congressional Budget Office report This summary is based largely on the summary provided by the Congressional Budget Office, a public domain source. H.R. 2019 would amend federal law to end the taxpayers' option to designate a portion of their federal income tax balance to the Presidential Election Campaign Fund and end the authority to spend funds on Presidential campaigns or conventions. The bill also would authorize the appropriation of $13 million a year over the 2014-2023 period for pediatric research. Procedural history The Gabriella Miller Kids First Research Act was introduced into the United States House of Representatives on May 16, 2013 by Rep. Gregg Harper (R, MS-3). It was referred to the United States House Committee on Energy and Commerce, the United States House Committee on House Administration, the United States House Committee on Ways and Means, and the United States House Energy Subcommittee on Health. On December 11, 2013, the House voted in Roll Call Vote 632 to pass the bill 295-103. On March 11, 2014, the United States Senate passed the bill by unanimous consent. President Barack Obama signed the bill into law on April 3, 2014, as . Debate and discussion According to Rep. Eric Cantor, the bill "clearly reflects Congressional priorities in funding: medical research before political parties and conventions." 102 House Democrats voted against the bill. The opposition, as stated in a Dear Colleague Letter, noted that the legislation had "completely bypassed the committee process," and therefore lacked the benefit of "discussion and debate as to what would be the most effective way of increasing financial support for pediatric biomedical research." Additional problems included the fact that the legislation "does not actually provide any additional funds to NIH. Rather, it specifies that the funds shall be available for NIH pediatric research "only to the extent and in such amounts as are provided in advance in appropriation Acts." The opposition also suggested that "perhaps this purely symbolic legislation is an